{
    "symbol": "DVAX",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-03 20:32:07",
    "content": " Lastly, I'm pleased to reiterate our 2022 full year financial guidance, including CpG 1018 adjuvant revenues, expected to be between $550 million and $600 million, with approximately 60% gross margin for the year, reflecting the economics associated with the remaining firm under our commercial supply agreements, R&D expenses in the range of $50 million to $60 million, SG&A expenses in the range of $130 million to $140 million and interest expense of approximately $7 million."
}